Immunitybio
As of the edition of 20 October 2026, Immunitybio runs 22 drugs, 1 of them marketed; it is on route A at 4 targets and on route B at 0 targets.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Family history
The records place 6 company names in this family.
Drugs by status
| Status | Count |
|---|---|
| Marketed | 1 |
| Active | 2 |
| Went quiet | 4 |
| Stopped | 15 |
| Total | 22 |
Marketed drugs and when their US protection ends
| Drug | US protection | Route B rows |
|---|---|---|
| Nogapendekin alfa inbakicept | Ends 2036 (computed from the first US licence) | 0 |
A route B row is one company at one target.
Where it needs a new molecule
Route A at 4 targets, route B at 0 targets.
All 4 rows on route A or B
In the product4 company-target rows on route A or B; 1 is not shown here, and no score is.
See all 4 targets where Immunitybio needs a new molecule, with the facts behind eachRequest access. Nothing is shown until you do.
Where its trials are
- Cancer: 50 trials led
- Digestive system: 18 trials led
- Hormones: 14 trials led